Alpha 2.0
Login Register
» Articles » PMID: 38142221

VERVE-101: a Promising CRISPR-based Gene Editing Therapy That Reduces LDL-C and PCSK9 Levels in HeFH Patients

Overview
Journal Eur Heart J Cardiovasc Pharmacother
Publisher Oxford University Press
Date 2023 Dec 23
PMID 38142221
Authors
Takahiro Horie
Koh Ono
Affiliations
Soon will be listed here.
Citing Articles

The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer's Disease: A Possible Target for the Disease Treatment.

Testa G, Giannelli S, Staurenghi E, Cecci R, Floro L, Gamba P Int J Mol Sci. 2025; 25(24.

PMID: 39769398 PMC: 11727734. DOI: 10.3390/ijms252413637.

Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy.

Bairqdar A, Karitskaya P, Stepanov G Int J Mol Sci. 2025; 25(24.

PMID: 39769084 PMC: 11678091. DOI: 10.3390/ijms252413321.

Advancements in -Based Anti-Tumor Gene Therapy Research.

Peng Y, Bai J, Li W, Su Z, Cheng X Molecules. 2024; 29(22).

PMID: 39598704 PMC: 11596491. DOI: 10.3390/molecules29225315.

Nanomedicine-based strategies for the treatment of vein graft disease.

Zhou Z, Chen W, Cao Y, Abdi R, Tao W Nat Rev Cardiol. 2024; .

PMID: 39501093 DOI: 10.1038/s41569-024-01094-y.

Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics.

Kumar A, Combe E, Mougene L, Zoulim F, Testoni B Viruses. 2024; 16(10).

PMID: 39459899 PMC: 11512240. DOI: 10.3390/v16101565.